Correlation Between Alnylam Pharmaceuticals and Biomarin Pharmaceutical

Can any of the company-specific risk be diversified away by investing in both Alnylam Pharmaceuticals and Biomarin Pharmaceutical at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Alnylam Pharmaceuticals and Biomarin Pharmaceutical into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Alnylam Pharmaceuticals and Biomarin Pharmaceutical, you can compare the effects of market volatilities on Alnylam Pharmaceuticals and Biomarin Pharmaceutical and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Alnylam Pharmaceuticals with a short position of Biomarin Pharmaceutical. Check out your portfolio center. Please also check ongoing floating volatility patterns of Alnylam Pharmaceuticals and Biomarin Pharmaceutical.

Diversification Opportunities for Alnylam Pharmaceuticals and Biomarin Pharmaceutical

0.0

Correlation Coefficient

Alnylam Pharmaceuticals  Biomarin Pharmaceutical

Pay attention - limited upside

The 3 months correlation between Alnylam and Biomarin is 0.0. Overlapping area represents the amount of risk that can be diversified away by holding Alnylam Pharmaceuticals and Biomarin Pharmaceutical in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Biomarin Pharmaceutical and Alnylam Pharmaceuticals is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Alnylam Pharmaceuticals are associated (or correlated) with Biomarin Pharmaceutical. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Biomarin Pharmaceutical has no effect on the direction of Alnylam Pharmaceuticals i.e., Alnylam Pharmaceuticals and Biomarin Pharmaceutical go up and down completely randomly.

Pair Corralation between Alnylam Pharmaceuticals and Biomarin Pharmaceutical

Given the investment horizon of 90 days Alnylam Pharmaceuticals is expected to generate 0.83 times more return on investment than Biomarin Pharmaceutical. However, Alnylam Pharmaceuticals is 1.2 times less risky than Biomarin Pharmaceutical. It trades about 0.01 of its potential returns per unit of risk. Biomarin Pharmaceutical is currently generating about -0.18 per unit of risk. If you would invest  25,378  in Alnylam Pharmaceuticals on September 2, 2024 and sell it today you would lose (71.00) from holding Alnylam Pharmaceuticals or give up 0.28% of portfolio value over 90 days.

Time Period	3 Months [change]
Direction	Flat
Strength	Insignificant
Accuracy	100.0%
Values	Daily Returns

Alnylam Pharmaceuticals  vs.  Biomarin Pharmaceutical

Alnylam Pharmaceuticals

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Alnylam Pharmaceuticals has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of fairly strong basic indicators, Alnylam Pharmaceuticals is not utilizing all of its potentials. The latest stock price disturbance, may contribute to short-term losses for the investors.

Biomarin Pharmaceutical

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Biomarin Pharmaceutical has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of unfluctuating performance in the last few months, the Stock's basic indicators remain very healthy which may send shares a bit higher in January 2025. The recent disarray may also be a sign of long period up-swing for the firm investors.

Pair Trading with Alnylam Pharmaceuticals and Biomarin Pharmaceutical

The main advantage of trading using opposite Alnylam Pharmaceuticals and Biomarin Pharmaceutical positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Alnylam Pharmaceuticals position performs unexpectedly, Biomarin Pharmaceutical can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Biomarin Pharmaceutical will offset losses from the drop in Biomarin Pharmaceutical's long position.

The idea behind Alnylam Pharmaceuticals and Biomarin Pharmaceutical pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the AI Portfolio Architect module to use AI to generate optimal portfolios and find profitable investment opportunities.